New York, New Jersey Clinical Trials

A listing of New York, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 425 clinical trials
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

cancer
carboplatin paclitaxel
carcinosarcoma
paclitaxel
recurrent disease
Research Site
 (7.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +94 other locations
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

aphasia
dementia
pick's disease
progranulin
Irving Institute for Clinical and Translational Research
 (5.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +46 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

preventive medication
lasmiditan
treatment regimen
migraine
ly573144
Columbia University
 (5.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
hemophilia
fitusiran
antihemophilic factor
bethesda assay
Investigational Site Number 8400008
 (7.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

parenteral administration
proteasome inhibitor
antibiotics
dexamethasone
arginine
Investigational Site Number 8400006
 (7.1 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
hemophilia
fitusiran
antihemophilic factor
bethesda assay
Investigational Site Number 8400008
 (7.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (5.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +22 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (5.1 away)
  • 0 views
  • 01 Dec, 2025
  • +19 other locations
UAT Study

Bowen Test Study Overview

Formal Test Site - NY
 (3.1 away) Contact site
  • 0 views
  • 09 May, 2025
  • +7 other locations
None

Memorial Sloan Kettering Cancer Center
 (3.1 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations